VNDA
Vanda Pharmaceuticals Inc
5.20$
+0.5%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +24.1% | -1.3% | -2.4% | +61.7% | +45.7% | +10.3% | +11.3% | +6.8% | +2.2% | +1.2% | -25.5% | |
| – | +17.5% | +4.6% | -2.5% | +76.1% | +18.4% | +15.5% | +16.9% | +8.6% | -16.6% | +1.4% | -20.9% | |
| – | -16.5% | -20.5% | -16.8% | +81.4% | -26.1% | +35.4% | -14.7% | +159.3% | +0.6% | -24.7% | -17.1% | |
| – | +10.3% | -1.3% | +1.5% | +79.5% | +21.3% | +17.8% | +17.7% | +7.9% | -16.8% | -3.5% | -29.6% | |
| – | +346.9% | +24.1% | -13.2% | +63.5% | -8.4% | +13.9% | +8.1% | +3.2% | +1.9% | +37.9% | +15.9% | |
| – | -75.0% | -39.8% | +7.8% | +18.3% | +14.7% | +12.3% | -19.9% | +16.5% | +13.7% | +27.2% | +7.3% | |
| – | +87.5% | +9.7% | +5.8% | -16.8% | -12.5% | +7.0% | +199.4% | -79.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +45.0% | -28.2% | -6.3% | -5.9% | -6.1% | -6.4% | -6.9% | -7.5% | +553.8% | -6.0% | +2.6% | |
| – | +635.0% | -1.2% | -6.3% | -23.4% | +28.4% | +10.1% | +10.8% | +20.5% | -3.3% | +13.6% | +37.5% | |
| – | +559.1% | -1.9% | +39.8% | -24.7% | +12.2% | +10.8% | +12.9% | +22.9% | -4.1% | +14.0% | +45.2% | |
| – | – | – | – | – | – | -1.4% | +9.2% | +0.7% | +3.0% | +78.1% | +30.1% | |
| – | +336.4% | -6.1% | +494.4% | -82.1% | +62.2% | -82.2% | -11.8% | +1,271.9% | -43.7% | -51.0% | +41.2% | |
| – | – | +0.0% | -100.0% | – | – | – | – | – | – | – | – | |
| – | -17.3% | -1.3% | +0.0% | +109.6% | +49.2% | +10.3% | +11.4% | +4.4% | +3.4% | -1.2% | -39.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +15.2% | +2.8% | +3.0% | +18.6% | +3.4% | +0.6% | +3.1% | +0.1% | +1.0% | +1.0% | +1.3% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.